Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 58,523 shares of the medical equipment provider's stock after purchasing an additional 4,000 shares during the period. Ensign Peak Advisors Inc's holdings in Zimmer Biomet were worth $6,182,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ZBH. Franklin Resources Inc. raised its holdings in shares of Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Norges Bank purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $216,223,000. Dodge & Cox raised its holdings in shares of Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after purchasing an additional 2,044,645 shares during the last quarter. Sound Shore Management Inc. CT purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $81,447,000. Finally, FMR LLC raised its holdings in shares of Zimmer Biomet by 91.6% during the fourth quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock valued at $151,897,000 after purchasing an additional 687,675 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $0.05 during mid-day trading on Friday, reaching $96.78. 2,339,193 shares of the company's stock traded hands, compared to its average volume of 1,752,324. The stock has a 50 day moving average of $103.41 and a two-hundred day moving average of $105.87. The company has a market cap of $19.15 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.92 and a 12-month high of $121.30.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The business's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the business earned $1.94 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on ZBH. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a report on Tuesday, May 6th. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Robert W. Baird reduced their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $113.45.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.